Patents Assigned to EyePoint Pharmaceuticals, Inc.
-
Method of treating ocular conditions by administering an antibody that activates Tie2 and binds VEGF
Patent number: 11873334Abstract: The disclosure provides compositions comprising multi-specific compounds, including a compound that targets a phosphatase and a receptor tyrosine kinase agonist. Also provided are methods for the treatment of conditions associated with angiogenesis, comprising administering a multi-specific compound that targets a phosphatase and a receptor tyrosine kinase agonist.Type: GrantFiled: December 10, 2020Date of Patent: January 16, 2024Assignee: EYEPOINT PHARMACEUTICALS, INC.Inventor: Kevin Peters -
Patent number: 11666558Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for eye conditions associated with angiogenesis, for example, intraocular pressure, ocular hypertension, and glaucoma.Type: GrantFiled: January 15, 2021Date of Patent: June 6, 2023Assignee: EyePoint Pharmaceuticals, Inc.Inventor: Kevin Peters
-
Patent number: 11613534Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for vascular disorders that can include, for example, retinopathies, ocular edema, and ocular neovascularization.Type: GrantFiled: October 28, 2020Date of Patent: March 28, 2023Assignee: EyePoint Pharmaceuticals, Inc.Inventor: John M. Janusz
-
Patent number: 11413242Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP?. Further disclosed are formulations to increase the efficacy of the compounds that activate Tie-2 and inhibit HPTP?.Type: GrantFiled: June 23, 2020Date of Patent: August 16, 2022Assignee: EYEPOINT PHARMACEUTICALS, INC.Inventor: Kevin Peters
-
Publication number: 20220202724Abstract: This invention relates to a bioerodible drug delivery device that can be implanted in a patient at or near an area in need of treatment. The bioerodible drug delivery device can be used to deliver a wide variety of different pharmaceutically active agents, and can do so at a controlled rate and over an extended period of time. The bioerodible drug delivery device includes a bioerodible polymeric outer housing with one or more delivery ports for delivering the pharmaceutically active agent(s) contained therein. The polymer used as the bioerodible polymeric outer housing is not substantially degraded during the dosing of the pharmaceutically active agent(s) in the bioerodible drug delivery device. The invention also provides methods of making the bioerodible drug delivery device and using it for the treatment of diseases and disorders.Type: ApplicationFiled: March 17, 2022Publication date: June 30, 2022Applicant: EyePoint Pharmaceuticals, Inc.Inventors: Hong Guo, Jianbing CHEN
-
Patent number: 11298323Abstract: This invention relates to a bioerodible drug delivery device that can be implanted in a patient at or near an area in need of treatment. The bioerodible drug delivery device can be used to deliver a wide variety of different pharmaceutically active agents, and can do so at a controlled rate and over an extended period of time. The bioerodible drug delivery device includes a bioerodible polymeric outer housing with one or more delivery ports for delivering the pharmaceutically active agent(s) contained therein. The polymer used as the bioerodible polymeric outer housing is not substantially degraded during the dosing of the pharmaceutically active agent(s) in the bioerodible drug delivery device. The invention also provides methods of making the bioerodible drug delivery device and using it for the treatment of diseases and disorders.Type: GrantFiled: June 12, 2018Date of Patent: April 12, 2022Assignee: EYEPOINT PHARMACEUTICALS, INC.Inventors: Hong Guo, Jianbing Chen
-
Patent number: 11253502Abstract: Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for eye conditions, for example, intraocular pressure, ocular hypertension, and glaucoma.Type: GrantFiled: April 28, 2020Date of Patent: February 22, 2022Assignee: EYEPOINT PHARMACEUTICALS, INC.Inventor: Kevin Peters
-
Patent number: 11180551Abstract: The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.Type: GrantFiled: April 17, 2020Date of Patent: November 23, 2021Assignee: EyePoint Pharmaceuticals, Inc.Inventors: Kevin Peters, Michael Allen Flynn
-
Patent number: 10363163Abstract: The devices and methods described herein relate to injector devices for delivering payloads to a tissue.Type: GrantFiled: September 10, 2015Date of Patent: July 30, 2019Assignee: EYEPOINT PHARMACEUTICALS, INC.Inventors: Martin Nazzaro, Josh York, Ron Leblanc
-
Publication number: 20190201324Abstract: An injectable drug delivery device includes a core containing one or more drugs and one or more polymers. The core may be surrounded by one or more polymer outer layers (referred to herein as “coatings,” “skins,” or “outer layers”). In certain embodiments, the device is formed by extruding or otherwise preforming a polymeric skin for a drug core. The drug core may be co-extruded with the skin, or inserted into the skin after the skin has been extruded, and possibly cured. In other embodiments, the drug core may be coated with one or more polymer coatings. These techniques may be usefully applied to fabricate devices having a wide array of drug formulations and skins that can be selected to control the release rate profile and various other properties of the drugs in the drug core in a form suitable for injection using standard or non-standard gauge needles.Type: ApplicationFiled: December 27, 2018Publication date: July 4, 2019Applicant: EyePoint Pharmaceuticals, Inc.Inventors: Kang-Jye CHOU, Hong GUO, Paul ASHTON, Robert W SHIMIZU, David A WATSON
-
Publication number: 20180353431Abstract: This invention relates to a bioerodible drug delivery device that can be implanted in a patient at or near an area in need of treatment. The bioerodible drug delivery device can be used to deliver a wide variety of different pharmaceutically active agents, and can do so at a controlled rate and over an extended period of time. The bioerodible drug delivery device includes a bioerodible polymeric outer housing with one or more delivery ports for delivering the pharmaceutically active agent(s) contained therein. The polymer used as the bioerodible polymeric outer housing is not substantially degraded during the dosing of the pharmaceutically active agent(s) in the bioerodible drug delivery device. The invention also provides methods of making the bioerodible drug delivery device and using it for the treatment of diseases and disorders.Type: ApplicationFiled: June 12, 2018Publication date: December 13, 2018Applicant: EyePoint Pharmaceuticals, Inc.Inventors: Hong GUO, Jian Bing CHEN